Delivery Order SPE2DB25D3109-SPE2DB25FPKMW
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,352.00 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL, with an ultimate completion date of August 7, 2025. This non-competitive delivery order represents a firm fixed-price transaction issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $6,405.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 ml dosage. This is a non-set-aside, competitively awarded contract with a completion date of September 29, 2025, and performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded through open procurement. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order valued at $1,957.76 to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of HUMIRA (Adalimumab) prefilled pens at 40 mg/0.4 mL. This firm fixed-price delivery order represents a non-set-aside competitive award with an ultimate completion date of September 22, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- The Defense Logistics Agency awarded a $3,715.82 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL. This competitively awarded, firm fixed-price contract is set to conclude on October 28, 2025, with performance executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL formulation, valued at $6,797.70 with a firm fixed price structure. Awarded on September 15, 2025, this non-set-aside delivery order is scheduled for completion by September 16, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a $1,510.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL on June 3, 2025, with performance in Conshohocken, Pennsylvania. This is a firm fixed price, non-set-aside contract with a completion date of June 4, 2025. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order for HUMIRA Pen 40 mg/0.8 mL, valued at $1,574.50 under a firm fixed-price contract. The award was made on June 25, 2025, with an ultimate completion date of June 26, 2025. This non-set-aside contract is a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. Performance of this delivery...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB25FPKMWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, due for completion by June 2, 2025. The award was issued on May 30, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen regularly fulfills delivery orders for brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 5/30/25 |